Study finds itraconazole monitoring methods differ in dogs

A new study in the American Journal of Veterinary Research is putting a finer point on a problem many clinicians already suspect: the test method used for itraconazole therapeutic drug monitoring can materially affect the answer. In dogs with blastomycosis, researchers found that culture-based bioassay and LC-MS were not equivalent, raising the possibility that the same patient sample could lead to different dose decisions depending on which assay a laboratory uses. (pubmed.ncbi.nlm.nih.gov)

That question lands in an area where veterinary medicine has been building evidence but still lacks full standardization. Itraconazole remains a widely used first-line antifungal for canine blastomycosis, yet drug exposure is highly variable between dogs because of differences in absorption and metabolism. In a recent prospective University of Illinois study, dogs started at about 5 mg/kg/day, had levels checked after two weeks and then monthly, and most required dose adjustments; many needed more than one, even after initially reaching the target range. The authors concluded that repeat monitoring after any dosage change is important, and that the dose needed to maintain target concentrations may decrease over time. (pmc.ncbi.nlm.nih.gov)

The new AJVR paper extends that conversation by focusing on the assay itself. According to the abstract, the investigators retrospectively evaluated 97 samples from 14 dogs with blastomycosis and compared bioassay results with three LC-MS-derived variables, including itraconazole alone and metabolite-based measures. Their central finding was straightforward: the methods were not equivalent, and the choice of assay could influence dosage adjustments. That’s especially relevant because bioassay and chromatographic methods do not measure exactly the same thing. MiraVista’s veterinary itraconazole test is a bioassay, while LC-MS can quantify parent itraconazole and hydroxy-itraconazole separately. Earlier veterinary literature has also noted that bioassay values can run higher than chromatographic values because the active metabolite contributes to antifungal activity measured by the assay. (pubmed.ncbi.nlm.nih.gov)

There’s broader context here, too. The Illinois blastomycosis study described a target trough range of 2 to 7 μg/mL using bioassay, a range extrapolated from human medicine and adjusted for expected assay differences. The authors explicitly flagged a real-world period when LC-MS had to be used because bioassay was unavailable, noting that this could have led to different clinical decisions. They also pointed to other confounders that make itraconazole management messy in practice, including nonlinear pharmacokinetics, possible autoinhibition of metabolism, concurrent glucocorticoid use, and formulation changes during treatment. (pmc.ncbi.nlm.nih.gov)

Industry and clinical background support the idea that method choice matters because itraconazole management is already sensitive to multiple sources of variability. MiraVista positions its bioassay as a validated tool for monitoring antifungal therapy in veterinary patients, while prior pharmacokinetic work in dogs has shown marked differences among innovator, generic, and compounded itraconazole products. In one JVIM study, compounded itraconazole produced very low absorption and should not be considered a substitute for brand-name or generic formulations; the same paper emphasized that clinicians may need blood testing to confirm adequate exposure. (miravistavets.com)

Why it matters: For veterinary professionals, this study is less about choosing a “better” assay in the abstract and more about avoiding category errors in day-to-day care. If one lab reports a bioassay-based concentration and another reports LC-MS parent drug or parent-plus-metabolite values, using the same therapeutic cutoff across methods could push a clinician toward an unnecessary increase, an avoidable decrease, or a false sense of security. In blastomycosis cases, where treatment often runs for months and adverse effects such as hepatotoxicity are a real concern, that distinction can affect both safety and disease control. It also reinforces the need to document not just the number, but the method, formulation, timing of sampling, and any recent dose changes or interacting medications. (pmc.ncbi.nlm.nih.gov)

What to watch: The next step is likely assay-specific standard setting. Future work will need to define canine therapeutic targets that are tied to the actual method used, and ideally link those targets to outcomes such as remission, relapse, hepatotoxicity, and cost of care. Until then, practices using itraconazole monitoring may want to stay consistent with one laboratory method when possible, and interpret any switch in assay platform cautiously rather than as a simple apples-to-apples trend. That recommendation is an inference from the available data, but it’s a practical one supported by the non-equivalence finding and the broader variability already documented in canine itraconazole therapy. (pubmed.ncbi.nlm.nih.gov)